Posted On: 10/26/2015 12:15:50 PM
Post# of 72446
This just in from Accesswire. I think we're about to go from the "Short and Distort" phase to the "Pump and Dump" phase...anyone else sense this?
Cellceutix Due Diligence Report: False Accusations Cause Mayhem; Share Price Ready to Bounce
Accesswire
NEW YORK, NY / ACCESSWIRE / October 26, 2015 / Cellceutix Corp. (CTIX) a clinical stage biopharmaceutical company located in Beverly, Massachusetts developing innovative therapies in oncology, dermatology and antimicrobial applications, has recently published a response to Rosen Law Firm's filing for a class action lawsuit against the company. CTIX replied by stating the accusations of stock manipulation against the company are false and lack true facts.
Additionally, the company recently announced that it continues to progress towards starting a phase 3 study for Brilacidin intravenous (IV) in the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI). In September, Cellceutix submitted its initial Pediatric Study Plan (PSP) to the Food and Drug Administration (FDA) for the use of Brilacidin IV in the treatment of ABSSSI in children. Cellceutix agreed to submit the PSP during its end-of-phase 2 meeting with FDA in mid-July. The submission of the PSP is the first of many requirements in expanding the use of Brilacidin to children. The goal of phase 3 is to confirm the safety and efficacy of single-dose Brilacidin IV against a commonly used antibiotic in large groups of ABSSSI patients worldwide.
For a more detailed research report with analyst comments on Cellceutix Corp. please follow the link. There is no cost obligation required to view analyst brief:
http://bit.ly/-CTIX_Due_Diligence_Report
Cellceutix Due Diligence Report: False Accusations Cause Mayhem; Share Price Ready to Bounce
Accesswire
NEW YORK, NY / ACCESSWIRE / October 26, 2015 / Cellceutix Corp. (CTIX) a clinical stage biopharmaceutical company located in Beverly, Massachusetts developing innovative therapies in oncology, dermatology and antimicrobial applications, has recently published a response to Rosen Law Firm's filing for a class action lawsuit against the company. CTIX replied by stating the accusations of stock manipulation against the company are false and lack true facts.
Additionally, the company recently announced that it continues to progress towards starting a phase 3 study for Brilacidin intravenous (IV) in the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI). In September, Cellceutix submitted its initial Pediatric Study Plan (PSP) to the Food and Drug Administration (FDA) for the use of Brilacidin IV in the treatment of ABSSSI in children. Cellceutix agreed to submit the PSP during its end-of-phase 2 meeting with FDA in mid-July. The submission of the PSP is the first of many requirements in expanding the use of Brilacidin to children. The goal of phase 3 is to confirm the safety and efficacy of single-dose Brilacidin IV against a commonly used antibiotic in large groups of ABSSSI patients worldwide.
For a more detailed research report with analyst comments on Cellceutix Corp. please follow the link. There is no cost obligation required to view analyst brief:
http://bit.ly/-CTIX_Due_Diligence_Report
(0)
(0)
